|
Baseline |
Baseline |
Follow-up |
Follow-up |
Study outcomes |
r |
P-value
|
r |
P-value
|
Efficacy† and safety‡
|
0.013 |
0.914 |
0.018 |
0.885 |
Efficacy† and adherence§
|
0.194 |
0.106 |
-0.043 |
0.721 |
Efficacy† and satisfaction¶
|
0.164 |
0.171 |
0.021 |
0.865 |
Efficacy† and QoL |
-.055 |
0.646 |
-0.178 |
0.137 |
Safety‡ and adherence§
|
-0.06 |
0.62 |
-0.214 |
0.074 |
Safety‡ and satisfaction¶
|
-0.112 |
0.354 |
-0.263 |
<0.05* |
Safety‡ and QoL |
-0.723 |
<0.0001** |
-0.782 |
<0.0001** |
Adherence§ and satisfaction¶
|
0.173 |
0.15 |
0.682 |
<0.0001** |
Adherence§ and QoL |
-.063 |
0.6 |
0.323 |
<0.01** |
Satisfaction¶ and QoL |
-.053 |
0.66 |
0.298 |
<0.05* |
† Number of seizures ‡ Pediatric epilepsy side effects questionnaire
score § Morisky medication adherence score ¶ Satisfaction with
information about medicines score * statistically significant (Pearson
correlation test) at the level of
P -value <0.05 **
statistically significant (Pearson correlation test) at the level of
P -value <0.01